Preclinical evaluation of antisense bcl-2 as a chemosensitizer for patients with gastric carcinoma

Cancer

Volumn 101, Issue 10, 2004, Pages 2177-2186

  Kim, Ryungsa ^a   Emi, Manabu ^a   Tanabe, Kazuaki ^a   Toge, Tetsuya ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Antisense bcl 2; Apoptosis; Chemotherapy; Gastric carcinoma

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CISPLATIN; DEOXYURIDINE TRIPHOSPHATE DERIVATIVE; DOXORUBICIN; FLUOROURACIL; LIPOFECTIN; METHYLTHIAZOLDIPHENYLTETRAZOLIUM; MITOMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; TETRAZOLIUM; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASSAY; CANCER CELL CULTURE; CELL DEATH; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; STOMACH CARCINOMA; WEIGHT REDUCTION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CELL LINE, TUMOR; DNA, ANTISENSE; DRUG RESISTANCE, NEOPLASM; HUMANS; IN SITU NICK-END LABELING; MICE; MICE, NUDE; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; STOMACH NEOPLASMS;

EID: 7644231496     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20636     Document Type: Article

References (44)

1. Debatin KM, Poncet D, Kroemer G. Chemotherapy: targeting the mitochondrial cell death pathway. Oncogene. 2002; 21:8786-8803.
2. Kim R, Tanabe K, Uchida Y, Emi M, Inoue H, Toge T. Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy. Cancer Chemother Pharmacol. 2002;50:343-352.
3. Cleator S, Parton M, Dowsett M. The biology of neoadjuvant chemotherapy for breast cancer. Endocr Relat Cancer. 2002; 9:183-195.
4. Buchholz TA, Davis DW, McConkey DJ, et al. Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J. 2003;9:33-41.
5. Sartorius UA, Krammer PH. Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer. 2002;97: 584-592.
6. Chaudhary KS, Abel PD, Stamp GW, Lalani E. Differential expression of cell death regulators in response to thapsigargin and Adriamycin in Bcl-2 transfected DU145 prostatic cancer cells. J Pathol. 2001;193:522-529.
7. Schimmer AD, Munk-Pedersen I, Minden MD, Reed JC. Bcl-2 and apoptosis in chronic lymphocytic leukemia. Curr Treat Options Oncol. 2003;4:211-218.
8. Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, et al. BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood. 2002;100: 3935-3941.
9. Spets H, Stromberg T, Georgii-Hemming P, Siljason J, Nilsson K, Jernberg-Wiklund H. Expression of the bcl-2 family of pro- and anti-apoptotic genes in multiple myeloma and normal plasma cells: regulation during interleukin-6 (IL-6)-induced growth and survival. Eur J Haematol. 2002;69:76-89.
10. Huang CI, Neuberg D, Johnson BE, Wei JY, Christiani DC. Expression of bcl-2 protein is associated with shorter survival in nonsmall cell lung carcinoma. Cancer. 2003;98:135-143.
11. Leiter U, Schmid RM, Kaskel P, Peter RU, Krahn G. Anti-apoptotic bcl-2 and bcl-xL in advanced malignant melanoma. Arch Dermatol Res. 2000;292:225-232.
12. Catz SD, Johnson JL. BCL-2 in prostate cancer: a minireview. Apoptosis. 2003;8:29-37.
13. Wu J, Shao ZM, Shen ZZ, et al. Significance of apoptosis and apoptotic-related proteins, Bcl-2, and Bax in primary breast cancer. Breast J. 2000;6:44-52.
14. Dursun A, Poyraz A, Suer O, Sezer C, Akyol G. Expression of Bcl-2 and c-ErbB-2 in colorectal neoplasia. Pathol Oncol Res. 2001;7:24-27.
15. Konturek PC, Konturek SJ, Sulekova Z, et al. Expression of hepatocyte growth factor, transforming growth factor alpha, apoptosis related proteins Bax and Bcl-2, and gastrin in human gastric cancer. Aliment Pharmacol Ther. 2001;15: 989-999.
16. Ohtsu A, Shimada Y, Shirao K, et al., Japan Clinical Oncology Group Study (JCOG9205). Randomized Phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol. 2003;21:54-59.
17. Kim R, Murakami S, Ohi Y, Inoue H, Yoshida K, Toge T. A Phase II trial of low dose administration of 5-fluorouracil and cisplatin in patients with advanced and recurrent gastric cancer. Int J Oncol. 1999;15:921-926.
18. Bugat R. Irinotecan in the treatment of gastric cancer. Ann Oncol. 2003;14:37-40.
19. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology. 2000;58:191-197.
20. Kornek GV, Raderer M, Schull B, et al. Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer. Br J Cancer. 2002;86:1858-1863.
21. Roth AD, Ajani J. Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann Oncol. 2003;14:41-44.
22. Davies AM, Gandara DR, Lara PN Jr., Mack PC, Lau DH, Gumerlock PH. Antisense oligonucleotides in the treatment of non-small-cell lung cancer. Clin Lung Cancer. 2003;4: S68-S73.
23. Nahta R, Esteva FJ. Bcl-2 antisense oligonucleotides: a potential novel strategy for the treatment of breast cancer. Semin Oncol. 2003;30:143-149.
24. Kim R, Ohi Y, Inoue H, Toge T. Activation and the interaction of proapoptotic genes in modulating sensitivity to anticancer drugs in gastric cancer cells. Int J Oncol. 1999;15: 751-756.
25. Tanabe K, Kim R, Inoue H, Emi M, Uchida Y, Toge T. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs. Int J Oncol. 2003;22:875-881.
26. Kim R, Tanabe K, Uchida Y, Emi M, Toge T. Effect of Bcl-2 antisense oligonucleotide on drug-sensitivity in association with apoptosis in undifferentiated thyroid carcinoma. Int J Mol Med. 2003;11:799-804.
27. Kim R, Minami K, Nishimoto N, Toge T. Enhancement of antitumor effect by intratumoral administration of bax gene in combination with anticancer drugs in gastric cancer. Int J Oncol 2001;18:363-367.
28. Webb A, Cunningham D, Cotter F, et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet. 1997;349:1137-1141.
29. Kim R, Hirabayashi N, Nishiyama M, Jinushi K, Toge T, Okada K. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int J Cancer. 1992;50:760-766.
30. Wacheck V, Heere-Ress E, Halaschek-Wiener J, et al. Bcl-2 antisense oligonucleotides chemosensitize human gastric cancer in a SCID mouse xenotransplantation model. J Mol Med. 2001;79:587-593.
31. Skulachev VP. Cytochrome c in the apoptotic and antioxidant cascades. FEBS Lett. 1998;423:275-280.
32. Lee M, Hyun DH, Marshall KA, et al. Effect of overexpression of BCL-2 on cellular oxidative damage, nitric oxide production, antioxidant defenses, and the proteasome. Free Radic Biol Med. 2001;31:1550-1559.
33. Wright SC, Wang H, Wei QS, Kinder DH, Larrick JW. Bcl-2-mediated resistance to apoptosis is associated with glutathione-induced inhibition of AP24 activation of nuclear DNA fragmentation. Cancer Res. 1998;58:5570-5576.
34. Celli A, Que FG, Gores GJ, LaRusso NF. Glutathione depletion is associated with decreased Bcl-2 expression and increased apoptosis in cholangiocytes. Am J Physiol. 1998;275: G749-G757.
35. Zhou HB, Zhu JR. Paclitaxel induces apoptosis in human gastric carcinoma cells. World J Gastroenterol. 2003;9:442-445.
36. Salah-Eldin AE, Inoue S, Tsukamoto S, Aoi H, Tsuda M. An association of Bcl-2 phosphorylation and Bax localization with their functions after hyperthermia and paclitaxel treatment. Int J Cancer. 2003;103:53-60.
37. Rudin CM, Otterson GA, Mauer AM, et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol. 2002;13:539-545.
38. Marcucci G, Byrd JC, Dai G, et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood. 2003;101:425-432.
39. Chi KN, Gleave ME, Klasa R, et al. A Phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res. 2001;7:3920-3927.
40. Tauchi T, Sumi M, Nakajima A, Sashida G, Shimamoto T, Ohyashiki K. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells. Clin Cancer Res. 2003;9:4267-4273.
41. Hartmann G, Weeratna RD, Ballas ZK, et al. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol. 2000;164:1617-1624.
42. Ballas ZK, Rasmussen WL, Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol. 1996;157: 1840-1845.
43. Wacheck V, Krepler C, Strommer S, et al. Antitumor effect of G3139 Bcl-2 antisense oligonucleotide is independent of its immune stimulation by CpG motifs in SCID mice. Antisense Nucleic Acid Drug Dev. 2002;12:359-367.
44. Lai JC, Benimetskaya L, Santella RM, Wang Q, Miller PS, Stein CA. G3139 (oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent non-antisense manner. Mol Cancer Ther. 2003;2:1031-1043.